

ERJ

UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 5732**

Takashi KAWASUJI et al. : Docket No. 2002\_0288A

Serial No. 10/069,999 : Group Art Unit 1639

Filed March 1, 2002 : Examiner Jon Epperson

INTEGRASE INHIBITORS COMPRISING  
AROMATIC HETEROCYCLE DERIVATIVES

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.
6. ☐ Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.


Respectfully submitted,

Takashi KAWASUJI et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 14, 2005

Sheet 1 of 1 :		INFORMATION DISCLOSURE STATEMENT			
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)  Date Submitted to PTO: September 14, 2005		ATTY DOCKET NO. 2002_0288A		SERIAL NO. 10/069,999	
		APPLICANT Takashi KAWASUJI et al.			
		FILING DATE March 1, 2002		GROUP 1639	



U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<div style="font-size: 2em; transform: rotate(-15deg);">Duplicate</div>	AA	5,591,773	1/1997	Grunberger et al.			
	AB						

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<div style="font-size: 2em; transform: rotate(-15deg);">Duplicate</div>	AC	99/26943	6/1999	WO			
	AD	0 220 947	5/1987	EP			
	AE						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)		
<div style="font-size: 2em; transform: rotate(-15deg);">TLE</div>	AF	DATABASE CHEMABS, Chemical Abstract Service, Brbot-Saranovic et al., "Reactions of ethyl 2-hydroxy-4-(4-hydroxy-6-methyl-2-pyron-3-yl)-4-oxo-2-butenate with N-nucleophiles. Synthesis of isomeric pyronylpyrazoles and pyrano[4,3-c]pyrazoles" XP002285137 retrieved from STN Database Accession No. 1990:178768.
	AG	DATABASE CHEMABS, Chemical Abstract Service, Anderson et al., "Dihydroimidazoles in synthesis: C-acylation of lithiodihydroimidazoles" XP002285138 retrieved from STN Database Accession No. 1985:113372.
	AH	DATABASE CHEMABS, Chemical Abstract Service, Peresleni et al., "Structure tautomerism, and reactions of β-(3-nitropyrid-2-yl) and β-(3-nitropyrid-4-yl)pyruvic acid esters" XP002285139 retrieved from STN Database Accession No. 1974:436930.
	AI	Database Beilstein, Beilstein Institute for Organic Chemistry, XP002285141 Database Accession No. BRN 4550604, 1991.
	AJ	Database Beilstein, Beilstein Institute for Organic Chemistry, XP002285142 Database Accession No. BRN 6004225, 1993.
	AK	Database Beilstein Beilstein Institute for Organic Chemistry, XP002285143 Database Accession No. BRN 4820019, 1992.
<div style="font-size: 2em; transform: rotate(-15deg);">d</div>	AL	X. Chen et al., "A new procedure to enols of 2-acylmethyl-4,4-dimethyl-2-oxazolines under ultrasonically dispersed potassium system", Chinese Journal of Chemistry, Vol. 17, No. 1, pp. 80-83, January 1999.

EXAMINER <span style="font-size: 1.5em; transform: rotate(-15deg); display: inline-block; width: 100px; height: 100px; vertical-align: middle;"></span>	DATE CONSIDERED <span style="font-size: 1.5em; transform: rotate(-15deg); display: inline-block; width: 100px; height: 100px; vertical-align: middle;"></span>
---	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy, this form with next communication to applicant.

1651 <sup>2FV</sup>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Parent application of : Confirmation No. 5732  
Takashi KAWASUJI et al. : Docket No. 2002\_0288A  
Serial No. 10/069,999 : Group Art Unit 1651  
Filed March 1, 2002 :

INTEGRASE INHIBITORS COMPRISING  
AROMATIC HETEROCYCLE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication (*for U.S. National applications filed after June 30, 2003 and International applications that have entered U.S. National Stage after June 30, 2003*),
- ☐ each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**  
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and  
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or  
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☒ a European patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.
6. ☐ Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Takashi KAWASUJI et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/ck  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 15, 2004

Sheet 1 of 1							
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)  Date Submitted to PTO: September 15, 2004	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; padding: 2px;">ATTY DOCKET NO. 2002_0288A</td> <td style="width: 70%; padding: 2px;">SERIAL NO. 10/069,999</td> </tr> <tr> <td colspan="2" style="padding: 2px;">APPLICANT Takashi KAWASUJI et al.</td> </tr> <tr> <td style="width: 30%; padding: 2px;">FILING DATE March 1, 2002</td> <td style="width: 70%; padding: 2px;">GROUP 1651</td> </tr> </table>	ATTY DOCKET NO. 2002_0288A	SERIAL NO. 10/069,999	APPLICANT Takashi KAWASUJI et al.		FILING DATE March 1, 2002	GROUP 1651
ATTY DOCKET NO. 2002_0288A	SERIAL NO. 10/069,999						
APPLICANT Takashi KAWASUJI et al.							
FILING DATE March 1, 2002	GROUP 1651						
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JB	AA	5,591,773	01/97	Grunberger et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES- NO	
JB	AG	99/26943	06/99	WO			
JB	AH	0220947	05/87	EP			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
JB	AI	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BRBOT-SARANOVIC, ANA ET AL: "Reactions of ethyl 2-hydroxy-4-(4-hydroxy-6-methyl-2-pyron-3-yl)-4-oxo-2-butenate with N-nucleophiles. Synthesis of isomeric pyronylpyrazoles and pyrano [4,3-c] pyrazoles" XP002285137					
	AJ	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ANDERSON, MICHAEL W. ET AL: "Dihydroimidazoles in synthesis: C-acylation of lithiodihydroimidazoles" XP002285138					
	AK	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PERESLENI, E. M. ET AL: "Structure, tautomerism, and reactions of .beta. -(3-nitropyrid-2-yl) and .beta. -(3-nitropyrid-4-yl) pyruvic acid esters" XP002285139					
	AL	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGRANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002285141					
	AM	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002285142					
d	AN	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002285143					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





PCJ  
JC20 Rec'd PCT/PTO 26 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Takashi KAWASUJI et al.

Serial No. 10/069,999

Filed March 1, 2002

:  
: Docket No. 2002-0288A  
: Group Art Unit Not Yet Assigned  
: Examiner Not Yet Assigned

INTEGRASE INHIBITORS COMPRISING  
AROMATIC HETEROCYCLE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,  
Washington, DC 20231

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, or
- (2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and  
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.


2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.
3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
- b. ☐ a foreign patent office search report (in the English language) submitted herewith,

- c. ☐ the concise explanation contained in the specification of the present application at page,
- d. ☐ the concise explanation set forth in the attached English language abstract,
- e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Takashi KAWASUJI et al.

By   
Warren M. Cheek, Jr.  
Registration No. 33,387  
Attorney for Applicants

WMC/gtn  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
March 26, 2002

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: March 26, 2002

ATTY DOCKET NO.  
2002-0288ASERIAL NO.  
10/069,999APPLICANT  
Takashi KAWASUJI et al.FILING DATE  
March 1, 2002

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA		5,480,887	1/1996				
AB		5,780,640	7/1998				
AC							

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	2113687	8/1983	GB			
	AK						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	K Hirai et al. "Synthesis of 2-Disubstituted-amino-4-arylthiazol-5-yl-alikanoic Acids", Chem. Pharm. Bull., Vol. 25, No. 9, pp. 2292-2299, 1977.
AP	F. R. Heitzler, "Preparation of non-symmetrical 2,3-bis (2,2'-oligopyridyl)pyrazines via 1,2-disubstituted ethanones" Synlett, No. 8, pp. 1203-1206, August 1999.
AQ	X. Chen et al., "A new procedure to enols of 2-acylmethyl-4,4-dimethyl-2-oxazolines under ultrasonically dispersed potassium system", Chin. J. Chem., Vol. 17, No. 1, pp. 80-83, January 1999.
AO	S. K. Bertilsson et al., "Chiral N,N'- and N,O-Bidentate Anionic Ligands. "Preparation, Metal Complexation, and Evaluation in the Asymmetric Aziridination of Olefins Organometallics", Vol. 18, No. 7, pp. 1281-1286, March 1999.
AP	Chemical Abstracts, Vol. 117, 1992, Abstract No. 171384, Registry No. 143814-20-4.
AQ	Chemical Abstracts, Vol. 114, 1991, Abstract No. 122162, Registry No. 129884-23-7 129884-21-5.
AP	Chemical Abstracts, Vol. 108, 1988, Abstract No. 150582, Registry No. 111559-36-5 111559-35-4.
AQ	Chemical Abstracts, Vol. 105, 1986, Abstract No. 6436, Registry No. 102720-85-4.

EXAMINER

DATE CONSIDERED

10/1/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: March 26, 2002

ATTY DOCKET NO.  
2002-0288A.SERIAL NO.  
10/069,999APPLICANT  
Takashi KAWASUJI et al.FILING DATE  
March 1, 2002

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	BH							
	BI							
	BJ							
	BK							
	BL							

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	BM	Chemical Abstracts, Vol. 103, 1985, Abstract No. 21944, Registry No. 95589-69-8.
✓	BN	Chemical Abstracts, Vol. 101, 1984, Abstract No. 211021, Registry No. 93074-95-4.
	BO	Chemical Abstracts, Vol. 100, 1984, Abstract No. 85565, Registry No. 88474-13-9.
✓	BP	Chemical Abstracts, Vol. 90, 1979, Abstract No. 72026, Registry No. 69097-74-1 69097-73-0 69097-72-9.
EXAMINER	DATE CONSIDERED 10/1/03	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1448 (modified)

ATTY DOCKET NO.  
2002-0288ASERIAL NO.  
10/069,999U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: March 26, 2002

APPLICANT  
Takashi KAWASUJI et al.FILING DATE  
March 1, 2002

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	CD						
	CE						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

JK	CF	Gordon N. Walker et al., "Synthesis of Benzo[f]quinolines and Ergolines from 5-Phenyl-6-methyl-2-pyridones", J. Org. Chem., Vol. 26, pp. 4441-4456, November 1961.
	CG	Rodolfo Nesi et al., "Thermal Rearrangement of Ethyl 5-Nitro-4-phenyl-2-oxa-3-azabicyclo[3.1.0]hex-3-ene-1-carboxylate into a Quinoxaline System", J. Chem. Soc. Chem. Commun., Vol. 23, pp. 1675-1676, July 1990.
✓	CH	Ana Brbot-Saranovic et al., "Reactions of Ethyl 2-Hydroxy-4-(4-Hydroxy-6-Methyl-2-Pyron-3-YL)-4-Oxo-2-Butenoate With N-Nucleophiles. Synthesis of Isomeric Pyronylpyrazoles and Pyrano[4,3-c]Pyrazoles", Heterocycles, Vol. 29, No. 8, pp. 1559-1571, April 1989.
✓	CI	Rok Zupet et al., "A Convenient Synthesis of Alkyl Heteroarylpyruvates" Synthetic Communications, 22(15), pp. 2245-2251, April 1992
✓	CJ	Johannes Meiwes et al., "Asymmetric synthesis of L-thienylalanines", Tetrahedron Assemetry, Vol. 8, No. 4, pp. 527-536, January 1997.
✓	CK	V. Boekelheide et al., "Synthesis of Pyrrocolines Unsubstituted in the Five-membered Ring", J. Am. Chem. Soc., Vol. 81, pp. 1456- 1459, March 1959.
✓	CL	Roger Adams et al., "Condensation Reactions of Picoline 1-Oxides", J. Am. Chem. Soc., Vol. 76, pp. 3168-3171, June 1954.
	CM	Helvetica Chimica Acta, "Vol. 38, No. 176, pp. 1452-1472, 1955.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Takashi KAWASUJI et al.

Serial No. NEW

Filed March 1, 2002

Attn: BOX PCT

Docket No. 2002\_0288A

INTEGRASE INHIBITORS COMPRISING  
AROMATIC HETEROCYCLE DERIVATIVES  
[Corresponding to PCT/JP00/05754  
Filed August 25, 2000]

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in international application no. PCT/JP00/05754.

- 1a. ☒ This Information Disclosure Statement is submitted:
- within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or
  - before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,
  - and thus no certification and/or fee is required.

ATTACHMENT C

1b. ☐ This Information Disclosure Statement is submitted after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, or

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted: after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.



4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Takashi KAWASUJI et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
March 1, 2002

Rec'd PCT/PTO 01 MAR 2002

Sheet 1 of 2

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: March 1, 2002

ATTY DOCKET NO.  
2002\_0288ASERIAL NO.  
NEWAPPLICANT  
Takashi KAWASUJI et al.FILING DATE  
March 1, 2002

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AD Invt. 1/06	AA	5,480,887	1/1996				
AD Invt. 1/06	AB	5,780,640	7/1998				
	AC						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
JB	AJ	2113687	8/1983	GB			
	AK						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

DE	AO	K Hirai et al. "Synthesis of 2-Disubstituted-amino-4-arylthiazol-5-yl-alikanoic Acids", Chem. Pharm. Bull., Vol. 25, No. 9, pp. 2292-2299, 1977.					
	AP	F. R. Heirtzler, "Preparation of non-symmetrical 2,3-bis (2,2'-oligopyridyl)pyrazines via 1,2-disubstituted ethanones" Synlett, No. 8, pp. 1203-1206, August 1999.					
	AQ	X. Chen et al., "A new procedure to enols of 2-acylmethyl-4,4-dimethyl-2-oxazolines under ultrasonically dispersed potassium system", Chin. J. Chem., Vol. 17, No. 1, pp. 80-83, January 1999.					
	AO	S. K. Bertilsson et al., "Chiral N,N'- and N,O-Bidentate Anionic Ligands. "Preparation, Metal Complexation, and Evaluation in the Asymmetric Aziridination of Olefins Organometallics", Vol. 18, No. 7, pp. 1281-1286, March 1999.					
	AP	Chemical Abstracts, Vol. 117, 1992, Abstract No. 171384, Registry No. 143814-20-4.					
	AQ	Chemical Abstracts, Vol. 114, 1991, Abstract No. 122162, Registry No. 129884-23-7 129884-21-5.					
	AP	Chemical Abstracts, Vol. 108, 1988, Abstract No. 150582, Registry No. 111559-36-5 111559-35-4.					
	AQ	Chemical Abstracts, Vol. 105, 1986, Abstract No. 6436, Registry No. 102720-85-4.					
EXAMINER				DATE CONSIDERED	AD 1/1/05		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: March 1, 2002

ATTY DOCKET NO.  
2002\_0288ASERIAL NO.  
NEWAPPLICANT  
Takashi KAWASUJI et al.FILING DATE  
March 1, 2002

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BH						
	BI						
	BJ						
	BK						
	BL						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

JL	BM	Chemical Abstracts, Vol. 103, 1985, Abstract No. 21944, Registry No. 95589-69-8.
I	BN	Chemical Abstracts, Vol. 101, 1984, Abstract No. 211021, Registry No. 93074-95-4.
	BO	Chemical Abstracts, Vol. 100, 1984, Abstract No. 85565, Registry No. 88474-13-9.
C	BP	Chemical Abstracts, Vol. 90, 1979, Abstract No. 72026, Registry No. 69097-74-1 69097-73-0 69097-72-9.
EXAMINER	DATE CONSIDERED 10/1/85	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.